District Court of Delaware rules that Actavis does not infringes with their Suboxone® and Subutex® generics
Annual Report
Orexo Ruling Hugely Significant | Potter Clarkson
Orexo partners with Gaia on digital opioid abuse therapeutic | Pharmaphorum
Orexo AB - Org Chart, Teams, Culture & Jobs | The Org
OREXO AB (PUBL)
Orexo launches digital therapies for depression, alcohol misuse early in US | pharmaphorum
Fast-dissolving opioid dependence tablet wins EU recommendation - Drug Delivery Business
Orexo sues Actavis and Teva over narcotic dependency treatment
Orexo soars after winning opioid drug appeal against Teva | Reuters
Cancer Pain Diagnostics Market 2022 Structure with Top Industry
Patent Litigation Updates: CRISPR, Acorda's Ampyra, and Orexo Versus Teva | BioSpace
Orexo misses out on millions after losing patent infringement suit against Actavis
Opioid Use Disorder Market Growth to register a CAGR of 8.7% to reach USD US$ 4,911.8 Million by 2028 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, | Medgadget
Orexo removes overhang on shares with key court win | Evaluate
Opioid Use Disorder Market Is Booming Worldwide 2023-2030 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. - Digital Journal
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Type headline here
Orexo
Teva Can Challenge Validity of Orexo Patent (Corrected)
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OREXO AB and OREXO US, INC., Plaintiffs, ACTAVIS ELIZABETH LLC,
Teva, denying 'any liability,' set aside $646M for opioid settlements. Here's why | Fierce Pharma
Swedish Pharmaceutical Company: Orexo soars after winning opioid drug appeal against Teva, Health News, ET HealthWorld
Domstol afviser omhøring af patentsag mellem Teva og Novo-firmaet Orexo — MedWatch
Teva unloads plant, U.S. OTC line to PL Developments | Fierce Pharma
Teva kept quiet for weeks on forthcoming generics blow: report | Fierce Pharma
